Chinese medicine: Involved in a lawsuit of 139 million yuan entering the second instance stage.

The announcement by China Pharmaceutical states that, due to a contract dispute arising from performance compensation, the company filed a lawsuit against Tibet Tiansheng Taifeng Pharmaceutical Co., Ltd. and Xu Panfeng in October 2024. After the first instance judgment, both the company and Tibet Tiansheng have appealed within the statutory time limit, and the case has entered the second instance stage. The amount involved is RMB 139,404,100. As of the disclosure date of the announcement, the second instance has not yet been heard, and the final outcome is uncertain.